{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:37Z","timestamp":1793643337776,"version":"4.5.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HLX01 (HanliKang<jats:sup>\u00ae<\/jats:sup>) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results from the open-label extension part. Patients were randomised to either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or HLX01 plus CHOP (H-CHOP) every 21 days for up to six cycles. The primary efficacy endpoint was overall survival (OS), and secondary efficacy endpoint was progression-free survival (PFS). Of the 407 patients enrolled in HLX01-NHL03, 316 patients (H-CHOP\u2009=\u2009157; R-CHOP\u2009=\u2009159) were included in the 5-year follow-up for a median duration of 65.1 (range, 2.2\u201376.5) months. 96.5% of the patients had an International Prognostic Index (IPI) of 1 or 2, and 17.7% had bone marrow involvement. The 5-year OS rates were 81.0% (95% CI: 74.9\u201387.5%) and 75.4% (95% CI: 68.9\u201382.6%)( HR: 0.75, 95% CI 0.47\u20131.20; <jats:italic>p<\/jats:italic>\u2009=\u20090.23) while 5-year PFS rates were 77.7% (95% CI: 71.4\u201384.6%) and 73.0% (95% CI: 66.3\u201380.3%) (HR: 0.84, 95% CI 0.54\u20131.30; <jats:italic>p<\/jats:italic>\u2009=\u20090.43) in the H-CHOP and R-CHOP groups, respectively. Treatment outcomes did not differ between groups regardless of IPI score and were consistent with the primary analysis. H-CHOP and R-CHOP provided no significant difference in 5-year OS or PFS in previously untreated patients with low or low-intermediate risk DLBCL.<\/jats:p>","DOI":"10.1186\/s12885-024-11876-9","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T14:42:26Z","timestamp":1706107346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term outcomes with HLX01 (HanliKang\u00ae), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study"],"prefix":"10.1186","volume":"24","author":[{"given":"Yan","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizheng","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"11876_CR1","volume-title":"In: StatPearls","author":"SA Padala","year":"2022","unstructured":"Padala SA, Kallam A. Diffuse large B cell lymphoma. In: StatPearls. edn. Treasure Island (FL): StatPearls Publishing; 2022."},{"issue":"3","key":"11876_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429\u201334.","journal-title":"Am J Clin Pathol"},{"key":"11876_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00001813-200211002-00002","volume":"13","author":"T Cerny","year":"2002","unstructured":"Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of Rituximab. Anticancer Drugs. 2002;13:3\u201310.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"11876_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med"},{"issue":"12","key":"11876_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes Des Lymphomes De l\u2019Adulte. Blood. 2010;116(12):2040\u20135.","journal-title":"Blood"},{"key":"11876_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s12885-016-2523-7","volume":"16","author":"J Wu","year":"2016","unstructured":"Wu J, Song Y, Su L, Xu L, Chen T, Zhao Z, Zhang M, Li W, Hu Y, Zhang X, et al. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. BMC Cancer. 2016;16:537.","journal-title":"BMC Cancer"},{"issue":"4","key":"11876_CR7","first-page":"257","volume":"33","author":"ZX Cheng","year":"2012","unstructured":"Cheng ZX, Zou SH, Li F, Li JM, Wang JM, Chen FY, Cao JN, Wang C, Wei Z, Cheng YF. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up]. Zhonghua Xue Ye Xue Za Zhi. 2012;33(4):257\u201360.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"7","key":"11876_CR8","first-page":"707","volume":"43","author":"C Lymphoma","year":"2021","unstructured":"China Anti-cancer Association, Lymphoma C, Chinese Association for Clinical O, Medical Oncology Branch of Chinese International E. Promotion Association for M, Healthcare: [Clinical practice guideline for lympoma in China (2021 Edition)]. Zhonghua Zhong Liu Za Zhi. 2021;43(7):707\u201335.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"11876_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semarthrit.2016.01.002","volume":"45","author":"A Al-Sabbagh","year":"2016","unstructured":"Al-Sabbagh A, Olech E, McClellan JE, Kirchhoff CF. Development of biosimilars. Semin Arthritis Rheum. 2016;45:11\u2013S18.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"11876_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/19420862.2019.1578147","volume":"11","author":"Y Xu","year":"2019","unstructured":"Xu Y, Xie L, Zhang E, Gao W, Wang L, Cao Y, Xie MH, Jiang W, Liu S. Physicochemical and functional assessments demonstrating analytical similarity between Rituximab biosimilar HLX01 and the MabThera(R). MAbs. 2019;11(3):606\u201320.","journal-title":"MAbs"},{"issue":"3","key":"11876_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.21147\/j.issn.1000-9604.2021.03.11","volume":"33","author":"Y Shi","year":"2021","unstructured":"Shi Y, Zhang Q, Han X, Qin Y, Ke X, Su H, Liu L, Fu J, Jin J, Feng J, et al. Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma. Chin J Cancer Res. 2021;33(3):405\u201316.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"11876_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-020-00871-9","volume":"13","author":"Y Shi","year":"2020","unstructured":"Shi Y, Song Y, Qin Y, Zhang Q, Han X, Hong X, Wang D, Li W, Zhang Y, Feng J, et al. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. J Hematol Oncol. 2020;13(1):38.","journal-title":"J Hematol Oncol"},{"key":"11876_CR13","doi-asserted-by":"crossref","unstructured":"Deng W, Yang S, Yang C, Chen H, Huang G, Wu H, Chen J. Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: real-world clinical experience. J Oncol Pharm Pract 2022:10781552221110470.","DOI":"10.1177\/10781552221110470"},{"key":"11876_CR14","unstructured":"Henlius Receives NMPA. Approval for its first product HLX01\u2013The beginning of a New Era for Biosimilar [https:\/\/www.henlius.com\/en\/NewsDetails-1867-26.html]."},{"key":"11876_CR15","unstructured":"NMPA Has Accepted. The NDA of HLX01(Rituximab Injection) for the treatment of rheumatoid arthritis [https:\/\/www.henlius.com\/en\/NewsDetails-2921-26.html]."},{"issue":"Suppl 2","key":"11876_CR16","first-page":"1140","volume":"78","author":"X Zeng","year":"2019","unstructured":"Zeng X, Wang Y, Jiang Z, Zhang Z, He L, Zhang X, Lu X, Liu X, Xu J, Huang C, et al. SAT0139\u2005a multicentre, randomised, double-blind, parallel active-controlled clinical trial comparing pharmacokinetics, pharmacodynamics, safety and exploratory efficacy between HLX01 and Europe-sourced rituximab as a new indication in Chinese moderate to severe patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(Suppl 2):1140.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"11876_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00277-011-1375-0","volume":"91","author":"X Li","year":"2012","unstructured":"Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Ann Hematol. 2012;91(6):837\u201345.","journal-title":"Ann Hematol"},{"issue":"15","key":"11876_CR18","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.4103\/0366-6999.237401","volume":"131","author":"JQ Wu","year":"2018","unstructured":"Wu JQ, Song YP, Su LP, Zhang MZ, Li W, Hu Y, Zhang XH, Gao YH, Niu ZX, Feng R, et al. Three-year follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line treatment of diffuse large B-Cell lymphoma and Follicular Lymphoma in real-world clinical settings in China: a prospective, Multicenter, Noninterventional Study. Chin Med J (Engl). 2018;131(15):1767\u201375.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"11876_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.4143\/crt.2018.230","volume":"51","author":"X Li","year":"2019","unstructured":"Li X, Huang H, Xu B, Guo H, Lin Y, Ye S, Yi J, Li W, Wu X, Wang W, et al. Dose-dense Rituximab-CHOP versus Standard Rituximab-CHOP in newly diagnosed Chinese patients with diffuse large B-Cell lymphoma: a Randomized, Multicenter, open-label phase 3 trial. Cancer Res Treat. 2019;51(3):919\u201332.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"11876_CR20","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857\u201361.","journal-title":"Blood"},{"issue":"18","key":"11876_CR21","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Hoof AV, Sebban C, Solal-Celigny P, Bouabdallah R, Ferm\u00e9 C, Christian B, Lepage E, Tilly H, Morschhauser F, et al. Long-term results of the R-CHOP study in the treatment of Elderly patients with diffuse large B-Cell lymphoma: a study by the Groupe d\u2019Etude Des Lymphomes De l\u2019Adulte. J Clin Oncol. 2005;23(18):4117\u201326.","journal-title":"J Clin Oncol"},{"key":"11876_CR22","doi-asserted-by":"publisher","first-page":"e2200165","DOI":"10.1200\/GO.22.00165","volume":"8","author":"ME Cabrera","year":"2022","unstructured":"Cabrera ME, Pena C, Leon P, Lois V, Rojas H, Vega V, Pizarro A, Calderon S, Rojas C, Aspillaga A, et al. Diffuse large B-Cell lymphoma in Chile: the impact of combined CHOP plus Rituximab in the Public Health System. JCO Glob Oncol. 2022;8:e2200165.","journal-title":"JCO Glob Oncol"},{"issue":"11","key":"11876_CR23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) group. Lancet Oncol. 2011;12(11):1013\u201322.","journal-title":"Lancet Oncol"},{"issue":"1","key":"11876_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cpt.2022.09.006","volume":"1","author":"Y Shi","year":"2023","unstructured":"Shi Y, Chen H, Qin Y, Yang J, Liu P, He X, Zhou S, Zhou L, Zhang C, Song Y, et al. Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of Rituximab (2005\u20132018). Cancer Pathogenesis and Therapy. 2023;1(1):3\u201311.","journal-title":"Cancer Pathogenesis and Therapy"},{"issue":"23","key":"11876_CR25","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquieres H, Ziepert M, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041\u20138.","journal-title":"Blood"},{"issue":"6","key":"11876_CR26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3109\/0284186X.2014.978367","volume":"54","author":"G Hedstrom","year":"2015","unstructured":"Hedstrom G, Hagberg O, Jerkeman M, Enblad G, Swedish Lymphoma Study G. The impact of age on survival of diffuse large B-cell lymphoma - a population-based study. Acta Oncol. 2015;54(6):916\u201323.","journal-title":"Acta Oncol"},{"issue":"6","key":"11876_CR27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.canep.2015.08.015","volume":"39","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Howell D, Burton C, Patmore R, Roman E. Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol. 2015;39(6):1103\u201312.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"11876_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.21147\/j.issn.1000-9604.2019.01.10","volume":"31","author":"Y Shi","year":"2019","unstructured":"Shi Y, Han Y, Yang J, Liu P, He X, Zhang C, Zhou S, Zhou L, Qin Y, Song Y, et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res. 2019;31(1):152\u201361.","journal-title":"Chin J Cancer Res"},{"issue":"11","key":"11876_CR29","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/annonc\/mdu109","volume":"25","author":"R Vaidya","year":"2014","unstructured":"Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol. 2014;25(11):2124\u201333.","journal-title":"Ann Oncol"},{"issue":"7","key":"11876_CR30","doi-asserted-by":"publisher","first-page":"A888","DOI":"10.1016\/j.jval.2016.08.271","volume":"19","author":"W Chen","year":"2016","unstructured":"Chen W, Xu X. Cost-effectiveness of Rituximab in the treatment of diffuse large B-Cell Non-hodgkin\u2019s Lyphoma patients (Dlbcl) in China. Value Health. 2016;19(7):A888.","journal-title":"Value Health"},{"issue":"5","key":"11876_CR31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617\u201329.","journal-title":"Am J Hematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-11876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-11876-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-11876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T14:42:39Z","timestamp":1706107359000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-11876-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11876"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-11876-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"12 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was developed by the sponsor of the study, Shanghai Henlius Biotech, Inc. The study protocol was reviewed and approved by the relevant independent ethics committee at each participating study centre. Written informed consent was obtained from all study participants prior to screening. Data were collected by the site investigators who vouch for the completeness and accuracy of the data and the fidelity of the trial to the protocol. The sponsor analysed the data. The study was conducted in accordance with the Declaration of Helsinki, Guideline for Good Clinical Practice, and applicable national and local regulations for clinical trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}